Crossmark

Safety and effectiveness of efgartigimod in patients with generalized myasthenia gravis by autoantibody subtype: analysis of post-marketing surveillance in Japan

Crossref DOI link: https://doi.org/10.1038/s41598-026-67939-3

Published Online: 2026-08-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Teranishi, Hirofumi

Aoyagi, Ryohei

Harada, Daisuke
Funding

Funding for this research was provided by:

argenx Japan K.K.
License Information

Text and Data Mining valid from 2026-08-26

Accepted Manuscript valid from 2026-08-26
More Information

Article History

Received: 24 February 2026

Accepted: 19 August 2026

First Online: 26 August 2026

Declarations

Competing interests: Hirofumi Teranishi, Ryohei Aoyagi, and Daisuke Harada are fulltime employees of argenx Japan K.K.

Document is current

Any future updates will be listed below